{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Relatlimab + Nivolumab Combination Effective in Stage III Melanoma
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Learning Objectives
After completing this continuing education activity you will be able to:
- Interpret results from a trial evaluating the use of preoperative ipilimumab with nivolumab for patients with clinical stage III melanoma.
- Identify results from a recent trial evaluating the safety and efficacy of nivolumab and relatlimab in patients with resectable clinical stage III or oligometastatic stage IV melanoma.
Learning Outcomes
Seventy-five percent of participants will demonstrate knowledge of the use of relatlimab and nivolumab neoadjuvant immunotherapy for patients with resectable clinical stage III or oligometastatic stage IV melanoma by achieving a minimum score of 70% on the outcomes-based posttest.Disclosures
All authors, faculty, staff, and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.
Price:
$12.95
Credits:
- ANCC 1.0 CH
- DC - BON 1.0 CH
- FL - BON 1.0 CH
- GA - BON 1.0 CH
- NM - BON 1.0 CH
- SC - BON 1.0 CH
- WV - BOERN 1.0 CH
Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT1222
Published: December 2022
Expires: 12/5/2025
Sources:
Oncology Times
Required Passing Score: 4/5 (80%)